Navigation Links
Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Date:1/7/2011

RESEARCH TRIANGLE PARK, N.C., Jan. 7, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.

Under the expanded-access protocol developed in conjunction with the U.S. Food and Drug Administration (FDA), patients will receive treatment with CMX001 for any of 12 different dsDNA viral infections, including adenovirus (AdV), herpes viruses (cytomegalovirus (CMV), herpes simplex virus (HSV) and Epstein Barr virus), polyoma viruses (BK virus and JC virus), and pox viruses.  The CMX001-350 study will enroll 200 patients at major medical centers primarily in the United States.

CMX001 is being developed by Chimerix for dual-use as a broad-spectrum antiviral for the treatment of life-threatening viral infections in immunocompromised patients and as a medical countermeasure in the event of a smallpox outbreak.  Chimerix is currently conducting a Phase 2 dose-defining clinical study of CMX001 in immunocompromised hematopoietic stem cell transplant patients at risk of life-threatening infection with CMV, which has enrolled over 130 patients. Additionally, the Company is initiating a Phase 2 clinical study in immunocompromised pediatric and adult hematopoietic stem cell transplant patients with AdV infections.

"Data from this open-label clinical study will be a critical component of our strategy to develop CMX001 as a broad-spectrum antiviral agent," said Kenneth I. Moch, President and CEO of Chimerix.  "We anticipate that the CMX001-350 study will provide important supportive data for our overall clinical development program."

"CMX001 is exhibiting a favorable tolerability profile and signs of potent antiviral activity across our clinical studie
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ...  to their offering.       ... or gene silencing involves the use of ... cell, this material is processed into short ...
(Date:5/28/2015)... , May 28, 2015 ... world,s largest provider of health care products and ... practitioners, today reminded its customers that the Henry ... physicians and veterinarians who experience operational, logistical or ... storms in the South Central region of the ...
(Date:5/28/2015)... 28, 2015 AlloSource ®, one ... bone, skin and soft-tissue allografts for use in ... healing, today announced that AlloWrap® DS, its double-sided ... the high-cost reimbursement category. "Reimbursement ... their patients," said Kimberly French , Director ...
Breaking Medicine Technology:Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 2Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 3AlloSource Announces Milestone In Reimbursement For AlloWrap DS 2
... Robert Mazzacavallo has joined Veridiam as the company,s Chief ... of high-precision, fabricated assemblies and metal components, primarily serving ... aerospace and general industrial markets. , Before joining Veridiam, ... Camas, WA. At C-Tech, Bob worked closely with ...
... 3 Corgenix Medical Corporation (OTC Bulletin Board: CONX), ... will host a conference call on Thursday, November 12, ... financial and operating performance for the first quarter ended ... product development and marketing activities. , Corgenix invites all ...
Cached Medicine Technology:Veridiam Names Robert Mazzacavallo New CFO 2
(Date:5/29/2015)... 2015 On May 28th, TheCelebrityDresses.com released ... dresses and party dresses. Most of the styles in ... release includes more than 80 styles of sexy cocktail ... most popular design elements coming with the new release ... one shoulder design. Many of the new styles are ...
(Date:5/28/2015)... Kentucky (PRWEB) May 29, 2015 Recently, KORT ... on helping amputees regain their quality of life. The program ... may have had one for years, but are still having ... are nearly 2 million people living with limb loss in ... disease (54%) – including diabetes and peripheral arterial disease – ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Today the ... Data Book for the 2015 Main Residency Match®. ... and 28,906 were filled when the matching algorithm was ... 1,129 filled during the Match Week Supplemental Offer and ... , “We are pleased with the outcome of the ...
(Date:5/28/2015)... AMVETS National Executive Director Stewart Hickey ... Care established by Congress to examine how to best ... to the commission by Mitch McConnell, majority leader of ... only 15 voting members on the panel, which was ... of 2014. The goal of the commission is to ...
(Date:5/28/2015)... Success Strategies for Biosimilars Approval:, ... Webinar**, June 23, 2015 — 11:00 a.m. – ... June 23, 2015, FDAnews is offering the combined ... attorneys from the international law firm Duane Morris ... A Roadmap to the 351(k) Application Process. , ...
Breaking Medicine News(10 mins):Health News:TheCelebrityDresses.com Released New Collection of Cheap Bridesmaid and Party Dresses 2Health News:KORT Richmond Physical Therapy Adds New Program to Help Amputees 2Health News:NRMP Releases Results and Data: 2015 Residency Match: Record Number of Positions Filled 2Health News:NRMP Releases Results and Data: 2015 Residency Match: Record Number of Positions Filled 3Health News:AMVETS Executive Director Stewart Hickey Appointed to Congressional Commission on Care 2Health News:FDAnews Announces — Success Strategies for Biosimilars Approval: A Roadmap to the 351(k) Application Process Webinar, June 23, 2015 2Health News:FDAnews Announces — Success Strategies for Biosimilars Approval: A Roadmap to the 351(k) Application Process Webinar, June 23, 2015 3
... in 2008, - Initial Results from JZP-6 Phase III Clinical Trial ... Pipeline and Early-Stage Development Portfolio ... - 2008 Financial Guidance Provided, PALO ALTO, Calif., March ... comprehensive update,on its commercial activities and near-term product development pipeline,and provided ...
... Services users on display, MINNEAPOLIS, March 13 ... who used the free, professional,counseling from QUITPLAN(R) Services to ... the State Capitol. The exhibits are on display,from Sunday, ... Corridor of State,Capitol near the Rotunda., "The Capitol ...
... following is a,statement by Lois Aronstein, AARP New York ... $400 million Housing,Opportunity Fund to improve the availability of ... to provide needed opportunities,for low- and moderate-income New Yorkers ... will be administered by the State of New York ...
... Cross Blue Shield Members, PITTSBURGH, March 13 ... it has received a Brand Excellence Award from ... annual awards honor Blue,Cross and Blue Shield companies ... Cross and Blue Shield Brand image., "BCBSA ...
... initiative,to eliminate the prescription drug expense paid by poor ... on Capitol Hill., Reps. Lloyd Doggett (D-25th TX) ... are sponsoring HR 5604, the Medicare Part D Home,and ... corrects an apparent oversight in the Medicare Part D ...
... 13 Marathon Mark Leventhal, Esq.,Founder and ... http://www.attorneyweightloss.com -- the first in the ... by an attorney -- is featured on,the ... Lawyer ("YL") in an article,entitled "Accessible Accountability: ...
Cached Medicine News:Health News:Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation 2Health News:Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation 3Health News:Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation 4Health News:Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation 5Health News:Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation 6Health News:ClearWay Minnesota(SM) Celebrates QUITPLAN(R) Services at the Capitol 2Health News:ClearWay Minnesota(SM) Celebrates QUITPLAN(R) Services at the Capitol 3Health News:Highmark Receives Prestigious Brand Excellence Award 2Health News:ALFA Aims to Provide Relief to Seniors 2Health News:Leventhal Weight Loss Incorporated President Featured on Cover of Young Lawyer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: